Categorical covariates | n (%) | |
Gender | ||
Male | 80 (65.6) | |
Female | 42 (34.4) | |
Race | ||
Caucasian | 111 (91.0) | |
Other | 3 (1.6) | |
Unknown | 8 (6.6) | |
Tumor type | ||
NSCLC | 42 (34.4) | |
Melanoma | 51 (41.8) | |
UCC | 15 (12.3) | |
MPM | 13 (10.7) | |
SCLC | 1 (0.8) | |
Treatment | ||
Pembrolizumab (2 mg/kg Q3W) | 53 (43.4) | |
Pembrolizumab (200 mg flat Q3W) | 69 (56.6) | |
Prior systemic treatment | ||
None | 62 (50.8) | |
1 | 48 (39.3) | |
2 | 12 (9.8) | |
WHO performance status | ||
0 | 42 (34.4) | |
1 | 54 (44.3) | |
2 | 11 (9) | |
Unknown | 15 (12.3) | |
Cerebral metastases | ||
Present at baseline | 17 (13.9) | |
Absent at baseline (radiological evaluation was performed) | 31 (25.4) | |
Unknown | 74 (60.7) | |
Continuous covariates | Median (IQR) | n (%) |
Age (yr) | 69 (57–74) | 122 (100) |
Body weight (kg) | 80 (68–90) | 121 (99) |
Body surface area (m2) | 1.97 (1.81–2.12) | 119 (98) |
Creatinine (μmol/L) | 82 (69.5–99) | 121 (99) |
CKD (mL/min) | 78 (62.5–92) | 121 (99) |
Total protein (g/L) | 75 (71–79) | 99 (81) |
Albumine (g/L) | 42 (40–45) | 114 (93) |
LDH (U/L) | 238 (190.5–316.5) | 120 (98) |
Leucocytes (x109 cells/L) | 8.6 (6.6–10.9) | 116 (95) |
Baseline covariates of patients. Advanced-stage cancer patients were included that received pembrolizumab monotherapy.
CKD, CKD-EPI renal clearance; LDH, lactate dehydrogenase; MPM, malignant pleural mesothelioma; SCLC, small-cell lung cancer; UCC, urothelial cell cancer.